CN116457355B - 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物 - Google Patents

2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物

Info

Publication number
CN116457355B
CN116457355B CN202180063093.0A CN202180063093A CN116457355B CN 116457355 B CN116457355 B CN 116457355B CN 202180063093 A CN202180063093 A CN 202180063093A CN 116457355 B CN116457355 B CN 116457355B
Authority
CN
China
Prior art keywords
pyridin
amino
imidazo
ketone
fluorocyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180063093.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN116457355A (zh
Inventor
J·李
S·赵
K·林
A·Y·朴
加德·昌德夫·戈拉克什纳
H·南
Y·全
Y·黄
J·E·金
M·金
I·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Biotherapy Co ltd
Original Assignee
First Biotherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Biotherapy Co ltd filed Critical First Biotherapy Co ltd
Publication of CN116457355A publication Critical patent/CN116457355A/zh
Application granted granted Critical
Publication of CN116457355B publication Critical patent/CN116457355B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180063093.0A 2020-09-15 2021-09-14 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物 Active CN116457355B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078372P 2020-09-15 2020-09-15
US63/078,372 2020-09-15
PCT/IB2021/058378 WO2022058890A1 (en) 2020-09-15 2021-09-14 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds

Publications (2)

Publication Number Publication Date
CN116457355A CN116457355A (zh) 2023-07-18
CN116457355B true CN116457355B (zh) 2026-05-08

Family

ID=80739409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063093.0A Active CN116457355B (zh) 2020-09-15 2021-09-14 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物

Country Status (8)

Country Link
US (1) US11744824B2 (cg-RX-API-DMAC7.html)
EP (1) EP4214207A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541464A (cg-RX-API-DMAC7.html)
KR (1) KR20230067669A (cg-RX-API-DMAC7.html)
CN (1) CN116457355B (cg-RX-API-DMAC7.html)
AU (1) AU2021342777A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192158A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022058890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120603826A (zh) * 2022-12-30 2025-09-05 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用
KR20260114565A (ko) * 2023-11-15 2026-07-22 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 6,5-융합 헤테로아릴 유도체 및 이의 용도
TW202525805A (zh) * 2023-12-29 2025-07-01 大陸商廣州市聯瑞製藥有限公司 雙環類化合物及其製備方法和應用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089763A1 (en) * 2004-03-19 2005-09-29 Warner-Lambert Company Llc Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
KR20080002866A (ko) 2005-04-25 2008-01-04 노파르티스 아게 펩티드 데포르밀라제 (pdf) 억제제로서 유용한이미다조(1,2-a)피리딘 유도체
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ, インコーポレイテッド 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法
CA2825746A1 (en) 2011-01-26 2012-08-02 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridine derivative or pharmacologically acceptable salt thereof
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108084193A (zh) * 2017-12-19 2018-05-29 郭守东 一种brd4蛋白抑制剂
KR102906523B1 (ko) * 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089763A1 (en) * 2004-03-19 2005-09-29 Warner-Lambert Company Llc Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. ARQUES 等.The Reaction of 1-Amino-4,6-diphenyl-2-methylthiopyridinium Iodide with Substituted Acetonitriles.《Synthesis》.1981,(第11期),第910-912页,尤其是第910页化合物3b和3c,第911页表格. *
R. Belaroussi 等.Three successive and regiocontroled palladium cross-coupling reactions to easily synthesize novel series of 2,4,6-tris(het)aryl pyrido[10,20:1,5]pyrazolo [3,4-d]pyrimidines.《RSC Advances》.2018,(第8期),第732-741页,尤其是第733页流程图1中化合物4和5. *
RN:2102411-56-1;ACS;《STN Registry数据库》;20170719;第1页 *

Also Published As

Publication number Publication date
EP4214207A4 (en) 2024-10-02
CN116457355A (zh) 2023-07-18
JP2023541464A (ja) 2023-10-02
US11744824B2 (en) 2023-09-05
US20220087985A1 (en) 2022-03-24
EP4214207A1 (en) 2023-07-26
WO2022058890A1 (en) 2022-03-24
AU2021342777A1 (en) 2023-04-27
CA3192158A1 (en) 2022-03-24
KR20230067669A (ko) 2023-05-16
AU2021342777A9 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
AU2022228101B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
CN113454082B (zh) 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途
CN110869360B (zh) 作为rock抑制剂的苯乙酰胺类
AU2006232620A1 (en) Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
AU2025275262A1 (en) TYK2 inhibitors and uses thereof
EP2181112A1 (en) Triazolopyridine compounds and their use as ask inhibitors
CA2624649A1 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
CN102341400A (zh) 用作激酶抑制剂的吡咯并嘧啶化合物
CN116457355A (zh) 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物
TWI762534B (zh) 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物
WO2016011979A1 (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
WO2018229543A2 (en) Therapeutic inhibitory compounds
CN113768935B (zh) 免疫疾病的预防剂和/或治疗剂
JP2016507537A (ja) 置換アセチレン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用
EP4200299B1 (en) Compounds for prevention or treatment of neurodegenerative disorders
HK40096261A (en) 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
JP2020521818A (ja) プロテインキナーゼ阻害剤として有用なカルボン酸誘導体
HK40058868A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
HK40058868B (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
EA046543B1 (ru) Амидзамещенные гетероциклические соединения
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
HK1240121B (en) Prophylactic and/or therapeutic agent for immune diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096261

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant